IVERIC bio (ISEE) Tops Q4 EPS by 53c

IVERIC bio (NASDAQ: ISEE) reported Q4 EPS of $0.27, $0.53 better than the analyst estimate of ($0.26).

“We start 2021 with significant momentum as we continue to enroll patients into our Zimura GATHER2 clinical trial and now expect to complete enrollment in the third quarter of this year,” stated Glenn P. Sblendorio, Chief Executive Officer and President of Iveric Bio. “We are extremely encouraged by the progress of our clinical trial sites to enroll and retain patients. We continue to work with our investigators to provide a safe environment for patients, which we believe increases the patients’ comfort and confidence to participate in the GATHER2 clinical trial. We are committed to continuing patient enrollment and retention aggressively in the GATHER2 clinical trial while prioritizing patient safety.”

Pravin U. Dugel, M.D., Chief Strategy and Business Officer of Iveric Bio added, “Although bringing Zimura to patients suffering from geographic atrophy secondary to age-related macular degeneration remains our top priority, in 2021 and thereafter we will continue to explore the potential development of Zimura in earlier stages of age-related macular degeneration as well as neovascular (wet) macular degeneration. Additionally, in our IC-500 program, we are pursuing HtrA1 inhibition as a target in the treatment of GA and potentially earlier stages of AMD. We are focused on advancing our pipeline of both therapeutic and gene therapy product candidates for treating retinal diseases with the potential to create long-term shareholder value.”

For earnings history and earnings-related data on IVERIC bio (ISEE) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance